证券代码：600518 证券简称：康美药业 编号：临2025-035 康美药业股份有限公司 第十届监事会 2025 年度第三次临时会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 （一）审议通过《公司 2025 年第三季度报告》 表决结果：赞同票 3 票，反对票 0 票，弃权票 0 票。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《康美药业 2025 年第三季度报告》。 特此公告。 康美药业股份有限公司监事会 二〇二五年十月三十一日 1 康美药业股份有限公司（以下简称公司）第十届监事会 2025 年度第三次临 时会议于 2025 年 10 月 29 日以现场结合通讯表决方式召开，会议通知已于 2025 年 10 月 22 日以通讯、电话方式向公司各位监事发出。本次会议应当出席监事 3 名，实际出席监事 3 名，监事会主席何则正先生主持会议，本次会议的召开符合 《公司法》《公司章程》等相关文件的规定，作出的决议合法、有效。 二、监事会会议审议情况 ...

证券代码：600518 证券简称：康美药业 编号：临2025-034 二、董事会会议审议情况 （一）审议通过《公司 2025 年第三季度报告》 表决结果：赞同票 9 票，反对票 0 票，弃权票 0 票。 康美药业股份有限公司 本议案经董事会审计委员会审议通过。 第十届董事会 2025 年度第四次临时会议决议公告 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《康美药业 2025 年第三季度报告》。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 康美药业股份有限公司（以下简称公司）第十届董事会 2025 年度第四次临 时会议于 2025 年 10 月 29 日以现场结合通讯表决方式召开，会议通知已于 2025 年 10 月 22 日以通讯、邮件方式向公司各位董事发出。本次会议应当出席董事 9 名，实际出席董事 9 名，董事长赖志坚先生主持会议，公司全体监事、高级管理 人员列席会议，本次会议的召开符合《公司法》《公司章程》等相关文件的规定， 作出的决议合法、有效。 特此 ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥1,382,206,417.41, a decrease of 1.22% compared to the same period last year[3]. - The total profit for the period was ¥2,071,133.57, while the net profit attributable to shareholders was a loss of ¥3,819,080.55[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥34,318,121.40[3]. - The company's total profit for the reporting period reached 60.21 million, driven by the successful implementation of the "one body, two wings" strategy, which significantly improved operational efficiency and increased both revenue and gross margin[9]. - Net profit attributable to shareholders was 160.84 million, reflecting a year-on-year increase due to the rise in total profit[9]. - Other income decreased to 105.14 million, primarily due to adjustments in previous court rulings affecting reported other income[9]. - Investment losses amounted to 57.00 million, mainly due to reduced investment gains from debt settlements in the previous year[9]. - The net profit for the first three quarters of 2025 reached CNY 15,091,123.76, compared to CNY 8,110,876.11 in the same period of 2024, representing an increase of approximately 85.5%[24]. - Operating profit for the current period was CNY 31,731,784.63, a significant recovery from a loss of CNY 40,789,411.08 in the previous year[24]. - The net profit for the first three quarters of 2025 was a loss of ¥753,766.47, an improvement from a loss of ¥62,715,096.69 in the first three quarters of 2024[33]. Assets and Liabilities - The total assets at the end of the reporting period were ¥13,682,934,507.97, a decrease of 0.83% from the end of the previous year[5]. - The equity attributable to shareholders increased to ¥7,186,774,270.00, reflecting a growth of 0.18% compared to the previous year[5]. - Total current assets as of September 30, 2025, amounted to ¥13,438,832,425.34, an increase of 3.0% from ¥13,051,758,104.45 at the end of 2024[30]. - Total assets reached ¥17,265,998,408.94, compared to ¥16,927,317,642.43 at the end of 2024, indicating a growth of 2.0%[31]. - Total liabilities decreased to CNY 6,458,251,341.59 in 2025 from CNY 6,588,939,896.04 in 2024, reflecting a reduction of about 2.0%[20]. - The total equity of the company as of September 30, 2025, was ¥11,997,447,440.21, a slight decrease from ¥11,998,836,702.95 at the end of 2024[31]. Cash Flow - The company reported a cash flow from operating activities of ¥137,842,499.80 for the year-to-date period[3]. - Cash flow from operating activities showed significant improvement, attributed to increased cash receipts from sales and a substantial reduction in tax payments compared to the previous year[9]. - Cash flow from investing activities was negative at 309.45 million, largely due to the absence of cash inflows from the disposal of subsidiaries and idle assets compared to the previous year[9]. - Cash flow from operating activities generated a net inflow of CNY 137,842,499.80, contrasting with a net outflow of CNY 349,692,169.54 in the prior year[27]. - Total cash inflow from operating activities increased to 4,208,820,838.61 RMB in 2025 from 3,960,454,938.73 RMB in 2024, representing a growth of approximately 6.3%[34]. - The total cash outflow from operating activities decreased to 4,215,051,535.64 RMB in 2025 from 4,667,505,434.97 RMB in 2024, indicating improved cash management[34]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 300,150, with the top ten shareholders holding a significant portion of the company's shares[11]. - The largest shareholder, Guangdong Shennongshi Enterprise Management Partnership, holds 25.38% of the shares, totaling 3,509,413,788 shares[12]. Research and Development - Research and development expenses for the first three quarters of 2025 were CNY 32,691,882.64, slightly higher than CNY 32,164,804.25 in the same period of 2024[23]. - Research and development expenses for the first three quarters of 2025 were ¥25,007,274.17, compared to ¥22,940,395.00 in the same period of 2024, showing an increase of 9.0%[32]. Legal Matters - The company is actively pursuing litigation to recover compensation from responsible parties, with a claim amounting to 34.09 million currently under consideration by the court[14]. - The company is closely monitoring ongoing legal proceedings related to its financial disputes, including the case with Bohai International Trust Co., Ltd.[17]. Other Financial Metrics - The company reported a credit impairment loss of 30.06 million, which was lower than the previous year's losses related to debt settlements[9]. - The company received CNY 4,001,236,403.64 in cash from sales of goods and services, an increase from CNY 3,617,637,785.45 in the same period last year[26]. - The company reported a decrease in interest income to CNY 5,576,587.76 from CNY 12,151,440.71 in the previous year, reflecting a decline of approximately 54.0%[24]. - The company did not apply new accounting standards for the year 2025[36].

Group 1 - The core point of the article is that Kangmei Pharmaceutical reported a decline in revenue for the third quarter while showing growth in the first three quarters of the year [1] Group 2 - In the third quarter, the company's revenue was 1.382 billion yuan, a year-on-year decrease of 1.22% [1] - The net profit for the third quarter was a loss of 3.8191 million yuan [1] - For the first three quarters, the total revenue reached 3.96 billion yuan, reflecting a year-on-year increase of 2.22% [1] - The net profit for the first three quarters was 13.0823 million yuan, which represents a significant year-on-year growth of 160.84% [1]

Core Viewpoint - The Shanghai Municipal Medical Procurement Management Office announced that certain batches of traditional Chinese medicine (TCM) decoction pieces failed quality inspections, specifically highlighting five batches of He Huan Mi produced by Shanghai De Da Tang Guo Yao Co., Ltd [1][3]. Group 1: Quality Inspection Announcement - The Shanghai Municipal Drug Administration issued a notice regarding the third batch of drug quality inspections for 2025, listing non-compliant TCM decoction pieces [1]. - The announcement advises medical institutions to procure only quality-compliant TCM decoction pieces [1]. Group 2: Company Information - Shanghai De Da Tang Guo Yao Co., Ltd. is located at 2059 Huifeng West Road, Fengxian District, covering an area of 50 acres with a building area of 70,000 square meters, including a workshop area of 43,700 square meters and a warehouse area of over 14,400 square meters [3]. - The company has three independent production lines and a total investment of 300 million yuan [3]. - In 2012, the company was acquired by Kangmei Pharmaceutical Co., Ltd. (stock code 600518), becoming a wholly-owned subsidiary of Guangdong Guangyao Group [3]. Group 3: Legal Issues - Kangmei Pharmaceutical Co., Ltd. and its legal representative, Lai Zhijian, have been restricted from high consumption due to a construction contract dispute [5][7]. - The case is being handled by the Tongliao City Keqi District People's Court, with the execution case number (2025) Nei 0502 Zhi Huan 554 [7].

证券代码：600518 证券简称：康美药业 编号：临2025-033 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 10 月 10 日（星期五）至 10 月 16 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 kangmei@kangmei.com.cn 进行提问。公司将在业绩说明会上对投资者普遍关注 的问题进行回答。 康美药业股份有限公司（以下简称公司）已于 2025 年 8 月 30 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经 营成果、财务状况，公司计划于 2025 年 10 月 17 日（星期五）下午 15:00-16:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、业绩说明会类型 本次业绩说明会以网络互动形式召开，公司将针对 2025 年半年度经营成果、 财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围内就 投资者普遍关注的问题进行回答。 康美药业股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在 ...

Core Viewpoint - The company has received a compensation amounting to 4.6132 million yuan, which will positively impact its financial results for the fiscal year 2025 [2][3]. Group 1: Compensation Details - The compensation amount received by the company is 4.6132 million yuan [2]. - This compensation will be recognized as a one-time gain in the current financial period, affecting the company's profit for the fiscal year 2025 [4]. - The compensation represents 38.18% of the company's audited net profit for the most recent fiscal year [3]. Group 2: Impact on Financial Statements - According to relevant accounting standards, the compensation will be recorded in the current period's profit and loss statement, leading to a positive impact on the company's 2025 financial results [4]. - The final impact on the company's profit for 2025 will be confirmed by the annual auditing agency [4].

Core Viewpoint - Kangmei Pharmaceutical (600518.SH) has signed a lease agreement with Shenzhen Xin'an Industrial Co., Ltd. for operational needs, but the leased property is included in the demolition area due to the advancement of Shenzhen Metro Line 20 Phase II project [1] Group 1 - The company has amicably agreed to hand over the leased property to facilitate the landlord's demolition process [1] - The company has received a total compensation of 4.6132 million yuan from the landlord, which accounts for 38.18% of the company's audited net profit for the most recent fiscal year [1]

证券代码：600518 证券简称：康美药业 编号：临2025-032 康美药业股份有限公司 关于收到补偿款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 获得补偿款金额：461.32 万元。 公司于近日收到出租方支付的补偿款合计 461.32 万元，占公司最近一个会 计年度经审计净利润的比例为 38.18%。 二、补偿的类型及其对上市公司的影响 根据《企业会计准则》等相关规定，公司上述获得的补偿款将一次性计入当 期损益，预计对 2025 年度利润将产生一定的积极影响。 上述补偿具体的会计处理以及最终对公司 2025 年度损益的影响以年度审计 机构确认的结果为准。敬请广大投资者注意投资风险。 特此公告。 康美药业股份有限公司董事会 二〇二五年十月一日 1 对当期损益的影响：上述补偿款将一次性计入当期损益，最终对公司 2025 年度损益的影响以年度审计机构确认的结果为准。 一、获得补偿款的基本情况 康美药业股份有限公司（以下简称公司）由于日常经营需要，与深圳市新安 实业有限公司（以下简称出租方）签订房屋租赁 ...

Core Viewpoint - The China Securities Regulatory Commission (CSRC) is intensifying its regulatory enforcement against financial fraud and information disclosure violations, aiming to enhance market integrity and investor confidence [1][2][3]. Regulatory Framework - Recent legal reforms, including the new Securities Law and related regulations, have established a robust regulatory framework for capital markets, providing a solid basis for enforcement actions [2][3]. - The CSRC has issued over 2,200 administrative penalties for financial fraud and market manipulation during the 14th Five-Year Plan period, with fines totaling 41.4 billion yuan, marking increases of 58% and 30% respectively compared to the previous five-year period [2][3]. Enforcement Actions - The CSRC is focusing on severe violations such as financial fraud and insider trading, with notable cases leading to significant penalties, including a 2.25 billion yuan fine against Zhongke Huayuan Titanium Co., Ltd. for compliance violations [3][4]. - Since last year, the CSRC has investigated 67 delisted companies for illegal activities, with 33 cases referred for potential criminal prosecution [3][4]. Investor Protection - The regulatory bodies are enhancing investor protection mechanisms, including the introduction of new judicial interpretations and multi-faceted dispute resolution frameworks to support investor rights [5][6]. - Landmark cases, such as the special representative litigation against Kangmei Pharmaceutical, have resulted in substantial compensation for investors, demonstrating the effectiveness of the new protective measures [5][6]. Comprehensive Accountability - The CSRC is promoting a multi-layered accountability system that integrates administrative, civil, and criminal responsibilities to strengthen deterrence against securities violations [8][9]. - Over the past five years, the CSRC has referred more than 700 cases to law enforcement, leading to serious criminal accountability for numerous offenders [9]. Future Directions - Experts suggest that future regulatory efforts should focus on precise enforcement against financial fraud while ensuring that intermediary institutions fulfill their responsibilities as gatekeepers [4][6]. - There is a call for a "one-stop" platform for investor rights protection, integrating various forms of dispute resolution to facilitate easier access for small investors [7].